Insiders · Profile

Doyle Mittie

Chief Medical Officer at Avalo Therapeutics. Filing since 16 Mar 2026. CIK 0001918845

Company

Date

Role

Action

Shares

Amount

Of holding

AVTX Avalo Therapeutics, Inc.

28 Aug 2026

Chief Medical Officer

Sold on a plan

679

$13.58K

1.3%

AVTX Avalo Therapeutics, Inc.

17 Aug 2026

Chief Medical Officer

Sold on a plan

1,000

$20.00K

1.9%

AVTX Avalo Therapeutics, Inc.

10 Aug 2026

Chief Medical Officer

Sold on a plan

679

$13.58K

1.3%

AVTX Avalo Therapeutics, Inc.

27 Jul 2026

Chief Medical Officer

Sold on a plan

1,000

$20.00K

1.9%

AVTX Avalo Therapeutics, Inc.

30 Jun 2026

Chief Medical Officer

Sold on a plan

4,654

$93.08K

8.2%

AVTX Avalo Therapeutics, Inc.

23 Jun 2026

Chief Medical Officer

Sold on a plan

1,450

$26.10K

2.7%

AVTX Avalo Therapeutics, Inc.

28 May 2026

Chief Medical Officer

Sold on a plan

679

$10.86K

1.4%

AVTX Avalo Therapeutics, Inc.

15 May 2026

Chief Medical Officer

Sold on a plan

3,000

$56.28K

45.3%

AVTX Avalo Therapeutics, Inc.

6 May 2026

Chief Medical Officer

Sold on a plan

106,555

$2.20M

96.7%

AVTX Avalo Therapeutics, Inc.

5 May 2026

Chief Medical Officer

Sold on a plan

1,679

$26.86K

31.7%

AVTX Avalo Therapeutics, Inc.

6 Apr 2026

Chief Medical Officer

Sold on a plan

3,970

$71.51K

52.3%

AVTX Avalo Therapeutics, Inc.

1 Apr 2026

Chief Medical Officer

Sold on a plan

679

$10.86K

15.8%

AVTX Avalo Therapeutics, Inc.

16 Mar 2026

Chief Medical Officer

Sold on a plan

25,492

$411.61K

87.6%

13 decisions on file.